Dry-Powder of Chitosan-Coated Lipid-Core Nanocapsules Containing Dapsone: Development, Laser Diffraction Characterization and Analytical Quantification

Abstract

Analytical techniques are critical for ensuring physical and chemical stability of a drug both for assessing the stability of drug molecules and for quantifying and identifying the drug content in products. We proposed the development of dry-powders of lipid-core nanocapsules containing dapsone and coated with chitosan, as well as, the analytical quantification of dapsone in dry-powders with 1% and 2% (m/v) of leucine by high-performance liquid chromatography (HPLC). Size is the most relevant physicochemical property of nanoparticulated drug delivery systems. In this context, our results demonstrated that during the powders redispersion in water, could be observed that the mean particle diameters (DAP-LNC-CS-L1 and DAP-LNC-CS-L2) decreased with redispersion times increase. The spray-drying of the lipid-core nanocapsule formulations showed yields ranging from 58 ± 1.0 % (DAP-LNC-CS-L1) to 61 ± 1.5 % (DAP-LNC-CS-L2) indicating an efficient drying process. In this context, the analytical quantifications of dapsone in the dry powders of nanocapsules by HPLC showed that the dapsone content ranged from 92 ± 1.4% (DAP-LNC-CS-L2) to 95 ± 0.8% (DAP-LNC-CS-L1). Can be concluded that spray-drying process of DAP-LNC-CS-L1 and DAP-LNC-CS-L2 formulations showed an efficient aqueous dispersion of nanocapsule powders and the analytical quantification of dapsone in spray-dryed powders were higher than 90%.

Inovações farmacêuticas da dapsona no tratamento da hanseníase pediátrica: uma revisão integrativa

“…Em relação aos países em que os estudos selecionados para pesquisa foram desenvolvidos, destacou-se a Índia com aproximadamente 28,5% (Chappa et al, 2018;Mahore et al, 2021;Sindhuri & Supraneni, 2021;Tiwari et al, 2018), o Brasil 21,45% (Borges et al, 2013;Cé et al, 2019;Monteiro et al, 2012) Portugal 21,45% ( Chaves et al, 2017 ;Chaves et al, 2015;Vieira et al, 2016) enquanto alguns países apresentaram apenas 7,15%, sendo Canadá (Alarie et al, 2018), Itália (Chaves et al, 2019), Irã (Ranjbar et al, 2019), China (Li et al, 2020).…”

“…O resultado foi uma taxa de dissolução aumentada em comparação a DAP simples, e uma melhor solubilidade, sendo uma alternativa potencial a uma formulação oral convencional (Mahore, et al, 2021). Cé, et al (2019) produziu pós secos de nanocápsulas de núcleo lipídico de dapsona, revestidas com quitosona e leucina como adjuvante de secagem. A técnica usada foi a de secagem por pulverização, que serve para produzir pós de partículas que podem ser administradas pelas vias, nasal, pulmonar e oral.…”